Safety Evaluation of Vaccine Adjuvants

Vaccine Adjuvants and Delivery Systems

Volumn , Issue , 2006, Pages 421-444

  Lindblad, Erik B ^a  

^a Brenntag Biosector   (Denmark)

Author keywords

Adjuvant safety testing assays; pathogen associated molecular patterns (PAMPs); Vaccine adjuvant safety evaluation

Indexed keywords

EID: 84889333303     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470134931.ch18     Document Type: Chapter

References (106)

1. Foege, W.H., Millar, J.D. & Henderson, D.A. Smallpox eradication in West and Central Africa. Bull World Health Organ 1975 52(2), 209-222.
2. Rey, M., Guillaumont, P. & d'Intignano, B.M. Benefits of immunization versus risk factors in tetanus. Dev Biol Stand 1979 43, 15-23.
3. Van Wezel, A.L. Vaccines: quantities, production and costs. Trop Geogr Med 1985 Sep, 37(3), S35-S39.
4. Olive, C., Toth, I. & Jackson, D. Technological advances in antigen delivery and synthetic peptide vaccine developmental strategies. Mini Rev Med Chem 2001 Nov, 1(4), 429-438.
5. Francis, M.J., Fry, C.M., Rowlands, D.J., Bittle, J.L., Houghten, R.A., Lerner, R.A. et al. Immune response to uncoupled peptides of foot-and-mouth disease virus. Immunology 1987 May, 61(1), 1-6.
6. Haro, I. & Gomara, M.J. Different approaches to potentiate the immune response induced by a 12-mer synthetic peptide. Curr Protein Pept Sci 2000 Sep, 1(2), 125-137.
7. Medzhitov, R. & Janeway, C., Jr. Innate immune recognition: mechanisms and pathways. Immunol Rev 2000 Feb, 173, 89-97.
8. Heine, H. & Ulmer, A.J. Recognition of bacterial products by Toll-like receptors. Chem Immunol Allergy 2005 86, 99-119.
9. Mannhalter, J.W., Neychev, H.O., Zlabinger, G.J., Ahmad, R. & Eibl, M.M. Modulation of the human immune response by the non-toxic and non-pyrogenic adjuvant aluminium hydroxide: effect on antigen uptake and antigen presentation. Clin Exp Immunol 1985 Jul, 61(1), 143-151.
10. Vogel, F.R. & Pruett, M.F. A compendium of vaccine adjuvants and excipients. In Vaccine Design: The Subunit and Adjuvant Approach, Powell, M.F. & Newman, M.J., Eds., Plenum Press, New York, 1995, pp. 141-228.
11. Kensil, C.R. & Kammer, R. QS-21: a water-soluble triterpene glycoside adjuvant. Expert Opin Invest Drugs 1998 Sep, 7(9), 1475-1482.
12. Nixon, A., Zaghouani, H., Penney, C.L., Lacroix, M., Dionne, G., Anderson, S.A. et al. Adjuvanticity of stearyl tyrosine on the antibody response to peptide 503-535 from HIV gp160. Viral Immunol 1992 Summer, 5(2), 141-150.
13. Gupta, R.K., Relyveld, E.H., Lindblad, E.B., Bizzini, B., Ben-Efraim, S. & Gupta, C.K. Adjuvants: a balance between toxicity and adjuvanticity. Vaccine 1993 11(3), 293-304.
14. Moss, R.B., Giermakowska, W., Lanza, P., Turner, J.L., Wallace, M.R., Jensen, F.C., Theofan G., Richierl, S.P., Carlo, D.J. Cross-clade immune responses after immunization with a whole-killed gp120-depleted human immunodeficiency virus type-1 immunogen in incomplete Freund's adjuvant (HIV-1 immunogen, REMUNE) in human immunodeficiency virus type-1 seropositive subjects. Viral Immunol 1997 10(4), 221-228.
15. WHO. Immunological adjuvants. Report of a WHO scientific group. Tech Rep Ser 1976 595, 3-40.
16. Lindblad, E.B. Freund's adjuvants. In Vaccine Adjuvants: Preparation Methods and Research Protocols, O'Hagan, D.T., Ed., Humana Press, Totowa, NJ, 2000, pp. 49-63.
17. Soszynski, D., Kozak, W. & Szewczenko, M. Course of fever response to repeated administration of sublethal doses of lipopolysaccharides, polyinosinic:polycytidylic acid and muramyl dipeptide to rabbits. Experientia 1991 Jan 15, 47(1), 43-47.
18. Shaw, C.M., Alvord, E.C., Jr., Fahlberg, W.J. & Kies, M.W. Adjuvant-antigen relationships in the production of experimental "allergic" encephalomyelitis in the guinea pig. J Exp Med 1962 115, 169-179.
19. Pearson, C.M. Development of arthritis, periarthritis and periostitis in rats given adjuvants. Proc Soc Exp Biol Med 1956 91(1), 95-101.
20. Chaby, R. & Caroff, M. Lipopolysaccharides of Bordetella pertussis endotoxin. In Pathogenesis and Immunity in Pertussis, Wardlaw, A.C. & Parton, R., Eds., Wiley, New York, 1988, pp. 247-271.
21. Anderson, G.W. & Henderson, D.A. Report on oral polio vaccines. JAMA 1965 Jan 18, 191, 252-253.
22. Franklin, G.C. & Robertson, M.J. A mass vaccination campaign against poliomyelitis using the Sabin oral vaccine. Public Health 1965 Jan, 79, 81-99.
23. Maharaj, I., Froh, K.J. & Campbell, J.B. Immune responses of mice to inactivated rabies vaccine administered orally: potentiation by Quillaja saponin. Can J Microbiol 1986 May, 32(5), 414-420.
24. Gaunt, I.F., Grasso, P. & Gangolli, S.D. Short-term toxicity of Quillaja extract in rats. Food Cosmet Toxicol 1974 Oct, 12(5-6), 641-650.
25. Phillips, J.C., Butterworth, K.R., Gaunt, I.F., Evans, J.G. & Grasso, P. Long-term toxicity study of Quillaja extract in mice. Food Cosmet Toxicol 1979 Feb, 17(1), 23-27.
26. Drake, J.J., Butterworth, K.R., Gaunt, I.F., Hooson, J., Evans, J.G. & Gangolli, S.D. Long-term toxicity study quillaia extract in rats. Food Chem Toxicol 1982 Feb, 20(1), 15-23.
27. Aggerbeck, H., Gizurarson, S., Wantzin, J. & Heron, I. Intranasal booster vaccination against diphtheria and tetanus in man. Vaccine 1997 Feb, 15(3), 307-316.
28. Gizurarson, S., Tamura, S., Kurata, T., Hasiguchi, K. & Ogawa, H. The effect of cholera toxin and cholera toxin B subunit on the nasal mucosal membrane. Vaccine 1991 Nov, 9(11), 825-832.
29. Lindblad, E.B. Aluminium adjuvants: in retrospect and prospect. Vaccine 2004 Sep 9, 22(27-28), 3658-3668.
30. Collier, L.H., Polakoff, S. & Mortimer, J. Reactions and antibody responses to reinforcing doses of adsorbed and plain tetanus vaccines. Lancet 1979 Jun 30, 1(8131), 1364-1368.
31. Authier, F.J., Cherin, P., Creange, A., Bonnotte, B., Ferrer, X., Abdelmoumni, A. et al. Central nervous system disease in patients with macrophagic myofasciitis. Brain 2001 May, 124(Pt 5), 974-983.
32. Lindblad, E.B. Mineral adjuvants. In Immunopotentiators in Modern Vaccines, Schijns, V. & O'Hagan, D.T., Eds., Elsevier, New York, 2005, pp. 217-234.
33. Verdier, F., Burnett, R., Michelet-Habchi, C., Moretto, P., Fievet-Groyne, F. & Sauzeat, E. Aluminium assay and evaluation of the local reaction at several time points after intramuscular administration of aluminium containing vaccines in the Cynomolgus monkey. Vaccine 2005 Feb 3, 23(11), 1359-1367.
34. Goto, N., Kato, H., Maeyama, J., Shibano, M., Saito, T., Yamaguchi, J. et al. Local tissue irritating effects and adjuvant activities of calcium phosphate and aluminium hydroxide with different physical properties. Vaccine 1997 Aug-Sep, 15(12-13), 1364-1371.
35. Lindblad, E.B. Are mineral adjuvants triggering TLR2/TLR4 on dendritic cells by a secondary cascade reaction in vivo through the action of heat shock proteins and danger signals? Editorial letter. Vaccine 2006 24, 697-698.
36. Asea, A., Kraeft, S.K., Kurt-Jones, E.A., Stevenson, M.A., Chen, L.B., Finberg, R.W. et al. HSP70 stimulates cytokine production through a CD14-dependent pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med 2000 Apr, 6(4), 435-442.
37. Asea, A., Rehli, M., Kabingu, E., Boch, J.A., Bare, O., Auron, P.E. et al. Novel signal transduction pathway utilized by extracellular HSP70: role of Toll-like receptor (TLR) 2 and TLR4. J Biol Chem 2002 277(17), 15028-15034.
38. Naim, J.O., van Oss, C.J., Wu, W., Giese, R.F. & Nickerson, P.A. Mechanisms of adjuvancy: I. Metal oxides as adjuvants. Vaccine 1997 Aug, 15(11), 1183-1193.
39. Waite, D.C., Jacobson, E.W., Ennis, F.A., Edelman, R., White, B., Kammer, R. et al. Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21. Vaccine 2001 Jul 16, 19(28-29), 3957-3967.
40. Morton, D.B. & Griffiths, P.H. Guidelines on the recognition of pain, distress and discomfort in experimental animals and an hypothesis for assessment. Vet Rec 1985 Apr 20, 116(16), 431-436.
41. Bomford, R. Saponin and other haemolysins (vitamin A, aliphatic amines, polyene antibiotics) as adjuvants for SRBC in the mouse: evidence for a role for cholesterol-binding in saponin adjuvanticity. Int Arch Allergy Appl Immunol 1980 63(2), 170-177.
42. Shaw, C.M., Alvord, E.C., Jr. & Kies, M.W. Straight chain hydrocarbons as substitutes for the oil in Freund's adjuvants in the production of experimental "allergic" encephalomyelitis in the guinea pig. J Immunol 1964 Jan, 92, 24-27.
43. Dalsgaard, K. Assessment of the dose of the immunological adjuvant Quil A in mice and guinea pigs, using sheep red blood cells as model antigen. Zentralbl Veterinarmed B 1984 Oct, 31(9), 718-720.
44. Leenaars, P.P., Hendriksen, C.F., Koedam, M.A., Claassen, I. & Claassen, E. Comparison of adjuvants for immune potentiating properties and side effects in mice. Vet Immunol Immunopathol 1995 Sep, 48(1-2), 123-138.
45. Leenaars, M. Adjuvants in laboratory animals: evaluation of immunostimulatory properties and side effects of Freund's complete adjuvant and alternative adjuvants in immunization procedures. Doctoral dissertation, RIVM, The Netherlands, 1997.
46. White, R.G., Coons, A.H. & Connolly, J.M. Studies on antibody production: III. The alum granuloma. J Exp Med 1955 Jul 1, 102(1), 73-82.
47. Valtulini, S., Macchi, C., Ballanti, P., Cherel, Y., Laval, A., Theaker, J.M. et al. Aluminium hydroxide-induced granulomas in pigs. Vaccine 2005 Jun 10, 23(30), 3999-4004.
48. Lindblad, E.B. & Hau, J. Escaping from the use of Freund's complete adjuvant. In Progress in the Reduction Refinement and Replacement of Animal Experimentation, Balls, M., van Zeller, A.-M. & Halder, M.E., Eds., Elsevier Science, Amsterdam, 2000, pp. 1681-1685.
49. Vogelbruch, M., Nuss, B., Korner, M., Kapp, A., Kiehl, P. & Bohm, W. Aluminiuminduced granulomas after inaccurate intradermal hyposensitization injections of aluminium-adsorbed depot preparations. Allergy 2000 Sep, 55(9), 883-887.
50. Bomford, R. The comparative selectivity of adjuvants for humoral and cellmediated immunity. Clin Exp Immunol 1980 Feb, 39(2), 435-441.
51. Kobayashi, K., Kaneda, K. & Kasama, T. Immunopathogenesis of delayed-type hypersensitivity. Microsc Res Tech 2001 May 15, 53(4), 241-245.
52. Marcinkiewicz, J. Cell-mediated immunity: role of IL-3 and IL-6 in the regulation of contact sensitivity reaction. Folia Histochem Cytobiol 1990 28(3), 107-119.
53. Dinarello, C.A., Elin, A.J., Chedid, L. & Wolff, S.M. The pyrogenicity of the synthetic adjuvant muramyl dipeptide and two structural analogues. J Infect Dis 1978 38(6), 760-767.
54. Nishio, A. & Kanoh, S. Development changes in the febrile response to endotoxin in rabbit. Jpn J Physiol 1980 30(4), 645-653.
55. Matyas, G.R., Wassef, N.M., Rao, M. & Alving, C.R. Induction and detection of antibodies to squalene. J Immunol Methods 2000 Nov 1, 245(1-2), 1-14.
56. Asa, P.B., Wilson, R.B. & Garry, R.F. Antibodies to squalene in recipients of anthrax vaccine. Exp Mol Pathol 2002 Aug, 73(1), 19-27.
57. Baluna, R. & Vitetta, E.S. Vascular leak syndrome: a side effect of immunotherapy. Immunopharmacology 1997 Oct, 37(2-3), 117-132.
58. Edelman, R., Palmer, K., Russ, K.G., Secrest, H.P., Becker, J.A., Bodison, S.A. et al. Safety and immunogenicity of recombinant Bacille Calmette-Guerin (rBCG) expressing Borrelia burgdorferi outer surface protein A (OspA) lipoprotein in adult volunteers: a candidate Lyme disease vaccine. Vaccine 1999 Feb 26, 17(7-8), 904-914.
59. Pearson, C.M. & Wood, F.D. Studies of polyarthritis and other lesions induced in rats by injection of mycobacterial adjuvant: I. General clinical and pathological characteristics and some modifying factors. Arthritis Rheum 1959 2, 440-459.
60. Freund, J., Stern, E.R. & Pisani, T.M. Isoallergic encephalomyelitis and radiculitis in guinea pigs after one injection of brain and mycobacteria in water and oil emulsion. J Immunol 1947 57, 170-194.
61. Whitehouse, M.W., Orr, K.J., Beck, F.W. & Pearson, C.M. Freund's adjuvants: relationship of arthritogenicity and adjuvanticity in rats to vehicle composition. Immunology 1974 Aug, 27(2), 311-330.
62. Clements, C.J. & Griffiths, E. The global impact of vaccines containing aluminium adjuvants. Vaccine 2002 May 31, 20(Suppl 3), S24-S33.
63. Weibel, R.E., McLean, A., Woodhour, A.F., Friedman, A. & Hilleman, M.R. Tenyear follow-up study for safety of adjuvant 65 influenza vaccine in man. Proc Soc Exp Biol Med 1973 Sep, 143(4), 1053-1056.
64. Veronesi, R., Correa, A. & Alterio, D. Single dose immunization against tetanus: promising results in human trials. Rev Inst Med Trop Sao Paulo 1970 Jan-Feb, 12(1), 46-54.
65. Stanfield, J.P., Gall, D. & Bracken, P.M. Single-dose antenatal tetanus immunisation. Lancet 1973 Feb 3, 1(7797), 215-219.
66. Bienzle, U., Gunther, M., Neuhaus, R., Vandepapeliere, P., Vollmar, J., Lun, A. et al. Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology 2003 Oct, 38(4), 811-819.
67. Pharmacopeia Europa, 3rd ed. (Suppl), 2000, p. 1304.
68. Code of Federal Regulations, Title 21, vol. 7, sec. 610.15 (Constituent materials), rev. Apr 1, 2003.
69. Edelman, R. Vaccine adjuvants. Rev Infect Dis 1980 May-Jun, 2(3), 370-383.
70. Goldenthal, K., Cavagnaro, J.A., Alving, C. & Vogel, F.R. Safety evaluation of vaccine adjuvants: National Cooperative Vaccine Development Meeting Working Group. AIDS Res Hum Retroviruses 1993, 9(Suppl 1), S47-S51.
71. Frost, L., Johansen, P., Pedersen, S., Veien, N., Ostergaard, P.A. & Nielsen, M.H. Persistent subcutaneous nodules in children hyposensitized with aluminiumcontaining allergen extracts. Allergy 1985 Jul, 40(5), 368-372.
72. Bergfors, E., Trollfors, B. & Inerot, A. Unexpectedly high incidence of persistent itching nodules and delayed hypersensitivity to aluminium in children after the use of adsorbed vaccines from a single manufacturer. Vaccine 2003 Dec 8, 22(1), 64-69.
73. Bohler-Sommeregger, K. & Lindemayr, H. Contact sensitivity to aluminium. Contact Dermatitis 1986 Nov, 15(5), 278-281.
74. Aprile, M.A. & Wardlaw, A.C. Aluminium compounds as adjuvants for vaccines and toxoids in man: a review. Can J Public Health 1966 Aug, 57(8), 343-354.
75. Butler, N.R., Voyce, M.A., Burland, W.L. & Hilton, M.L. Advantages of aluminium hydroxide adsorbed combined diphtheria, tetanus, and pertussis vaccines for the immunization of infants. Br Med J 1969 Mar 15, 1(645), 663-666.
76. Shi, Y., HogenEsch, H., Regnier, F.E. & Hem, S.L. Detoxification of endotoxin by aluminum hydroxide adjuvant. Vaccine 2001 Feb 8, 19(13-14), 1747-1752.
77. Norimatsu, M., Ogikubo, Y., Aoki, A., Takahashi, T., Watanabe, G., Taya, K. et al. Effects of aluminum adjuvant on systemic reactions of lipopolysaccharides in swine. Vaccine 1995 Oct, 13(14), 1325-1329.
78. Martyn, C.N., Barker, D.J., Osmond, C., Harris, E.C., Edwardson, J.A. & Lacey, R.F. Geographical relation between Alzheimer's disease and aluminum in drinking water. Lancet 1989 Jan 14, 1(8629), 59-62.
79. Flarend, R.E., Hem, S.L., White, J.L., Elmore, D., Suckow, M.A., Rudy, A.C. et al. In vivo absorption of aluminium-containing vaccine adjuvants using 26Al. Vaccine 1997 Aug-Sep, 15(12-13), 1314-1318.
80. Coursaget, P., Yvonnet, B., Relyveld, E.H., Barres, J.L., Diop-Mar, I. & Chiron, J.P. Simultaneous administration of diphtheria-tetanus-pertussis-polio and hepatitis B vaccines in a simplified immunization program: immune response to diphtheria toxoid, tetanus toxoid, pertussis, and hepatitis B surface antigen. Infect Immun 1986 Mar, 51(3), 784-787.
81. Relyveld, E.H. Preparation and use of calcium phosphate adsorbed vaccines. Dev Biol Stand 1986 65, 131-136.
82. Tanzer, M., Gollish, J., Leighton, R., Orrell, K., Giacchino, A., Welsh, P. et al. The effect of adjuvant calcium phosphate coating on a porous-coated femoral stem. Clin Orthop Relat Res 2004 Jul(424), 153-160.
83. Friedewald, W.F. Adjuvants in immunization with influenza virus vaccines. J Exp Med 1944 80, 477-491.
84. Henle, W. & Henle, G. Effect of adjuvants on vaccination of human beings against influenza. Proc Soc Exp Biol NY 1945 59, 179-181.
85. Salk, J.E., Bailey, M.L. & Laurent, A.M. The use of adjuvants in studies on influenza immunization: II. Increased antibody formation in human subjects inoculated with influenza virus vaccine in a water-in-oil emulsion. Am J Hyg 1952 55(3), 439-456.
86. Davenport, F.M., Hennessy, A.V. & Bell, J.E. Immunologic advantages of emulsified influenza vaccines. Mil Med 1962 127, 95-100.
87. Davenport, F.M. Applied immunology of mineral oil adjuvants. J Allergy 1961 32, 177-189.
88. Bell, J.A., Philip, R.N., Davis, D.J., Beem, M.O., Bergelman, P.M., Engler, J.L. et al. Epidemiological studies on influenza in familial and general population groups: 4. Vaccine reactions. Am J Hyg 1961 73, 148-163.
89. Cutler, J.C., Lesesne, L. & Vaughn, I. Use of poliomyelitis virus vaccine in light mineral oil adjuvant in a community immunization program and report of reactions encountered. J Allergy 1962 33, 193-209.
90. Fukumi, H. Effectiveness and untoward reactions of oil adjuvant influenza vaccines. Symposium Series in Immunobiological Standardization, Karger, New York, 1967, pp. 237-240.
91. Meiklejohn, G. Adjuvant influenza adenovirus vaccine. JAMA 1962 179, 594-597.
92. Meiklejohn, G. Personal communication quoted in: Hilleman, MR. Critical appraisal of emulsified oil adjuvants applied to viral vaccines. Prog Med Virol 1966, 8, 157.
93. Pittman, M. Some remarks regarding the reaction provoking properties. Symposium Series in Immunobiological Standardization, Karger, New York, 1967, pp. 101-102.
94. Stuart-Harris, C.H. Adjuvant influenza vaccines. Bull World Health Organ 1969 41, 617-621.
95. Ogonuki, H., Hashizume, S. & Abe, H. Histopathological tests of tissues in the sites of local reactions caused by the injection of oil-adjuvant cholera vaccine. Symposium Series in Immunobiological Standardization, Karger, New York, 1967, pp. 125-128.
96. Beebe, G.W., Simon, A.H. & Vivona, S. Follow-up study on army personnel who received adjuvant influenza virus vaccine, 1951-1953. Am J Med Sci 1964 247, 385-405.
97. Potter, M. & Boyce, C.R. Induction of plasma-cell neoplasms in strain BALB/c mice with mineral oil and mineral oil adjuvants. Nature 1962 193, 1086-1087.
98. Bollinger, J.N. Metabolic fate of mineral oil adjuvants using 14C-labeled tracers: I. Mineral oil. J Pharm Sci 1970 59(8), 1084-1088.
99. Bollinger, J.N. Metabolic fate of mineral oil adjuvants using 14C-labeled tracers: II. Mannide monooleate. J Pharm Sci 1970 Aug, 59(8), 1088-1092.
100. Batista, A.D. & Lindblad, E.B. Analyzing toxicological aspects of immunological adjuvants for vaccine and experimental use. 2006 (submitted).
101. Stewart-Tull, D.E.S. Recommendations for the assessment of adjuvants (immunopotentiators). In Immunological Adjuvants and Vaccines, Gregoriadis A., Ed., Plenum Publishing Corporation, New York, 1989.
102. Shimada, H., Hattori, C. & Sato, T. Mutagenicity studies of muroctasin. Arzneimittelforschung 1988, 38(7a), 1031-1033.
103. Berlin, B.S. Tests for biologic safety of Arlacel A. Ann Allergy 1962 20, 472-479.
104. IPCS. Principles and methods for assessing allergic hypersensitization associated with exposure to chemicals. In Environmental Health Criteria, 1999, p. 212.
105. Bloksma, N., Kubicka-Muranyi, M., Schuppe, H.C., Gleichmann, E. & Gleichmann, H. Predictive immunotoxicological test systems: suitability of the popliteal lymph node assay in mice and rats. Crit Rev Toxicol 1995 25(5), 369-396.
106. Kimber, I. & Dearman, R.J. Immune responses: adverse versus non-adverse effects. Toxicol Pathol 2002 Jan-Feb, 30(1), 54-58.